Evidence map›Paper›PMID 34429335›Full record

ArticleLupus science & medicine2021

Development of a lupus nephritis suboptimal response prediction tool using renal histopathological and clinical laboratory variables at the time of diagnosis.

Lindsay N Helget, David J Dillon, Bethany Wolf, Laura P Parks, Sally E Self, Evelyn T Bruner, Evan E Oates, Jim C Oates

Abstract read
In one paragraph

Article in Lupus science & medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Artificial intelligence in glomerular diseases.Pediatric nephrology (Berlin, Germany) · 2022
    Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lindsay N HelgetDepartment of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
David J DillonDepartment of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
Bethany WolfDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.
Laura P ParksDepartment of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
Sally E SelfDepartment of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
Evelyn T BrunerDepartment of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
Evan E OatesVanderbilt University, Nashville, Tennessee, USA.
Jim C OatesDepartment of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA oatesjc@musc.edu.ORCID 0000-0002-5426-1359

Funding

South Carolina Clinical & Translational Research Institute (SCTR)UL1TR001450 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T., FLUME, PATRICK A · 2015 to 2024
$41.1M
SOUTH CAROLINA CLINICAL & TRANSLATIONAL RESEARCH INSTITUTE (SCTR)UL1RR029882 · NCRR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2009 to 2011
$10.1M
Resource CoreP30AR072582 · NIAMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI JAMES C OATES · 2017 to 2026
$8.5M
Patient Resource CoreP60AR062755 · NIAMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI GILKESON, GARY S · 2012 to 2016
$5.8M
Training Grant in Inflammatory and Fibrosing DiseasesT32AR050958 · NIAMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DIANE L KAMEN · 2005 to 2026
$4.2M
Role of reactive intermediates in lupus nephritisR01AR045476 · NIAMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI GILKESON, GARY S, OATES, JAMES C · 1999 to 2012
$3.5M
Predictive Biomarkers for disease activity and organ damage in patients with lupusR01AR071947 · NIAMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI OATES, JAMES C, ROVIN, BRAD H · 2018 to 2022
$3.2M
Role of nitric oxide and eicosanoids in lupus nepthritisK08AR002193 · NIAMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI OATES, JAMES C · 2001 to 2005
$635k
Urine biomarkers of lupus nephritis pathology and response to therapyI01CX000218 · VA · RALPH H JOHNSON VA MEDICAL CENTER · PI OATES, JAMES C · 2011 to 2013
–
Targeting Pathogenic Endothelial Dysfunction in Systemic Lupus ErythematosusI01CX001248 · VA · RALPH H JOHNSON VA MEDICAL CENTER · PI OATES, JAMES C · 2016 to 2025
–
CSRD VA I01 CX000218NCATS NIH HHS UL1 TR001450NCRR NIH HHS UL1 RR029882NIAMS NIH HHS K08 AR002193NIAMS NIH HHS P30 AR072582NIAMS NIH HHS P60 AR062755NIAMS NIH HHS R01 AR045476NIAMS NIH HHS R01 AR071947NIAMS NIH HHS T32 AR050958
6 · The paper itself

Abstract

objectiveLupus nephritis (LN) is an immune complex-mediated glomerular and tubulointerstitial disease in patients with SLE. Prediction of outcomes at the onset of LN diagnosis can guide decisions regarding intensity of monitoring and therapy for treatment success. Currently, no machine learning model of outcomes exists. Several outcomes modelling works have used univariate or linear modelling but were limited by the disease heterogeneity. We hypothesised that a combination of renal pathology results and routine clinical laboratory data could be used to develop and to cross-validate a clinically meaningful machine learning early decision support tool that predicts LN outcomes at approximately 1 year.

methodsTo address this hypothesis, patients with LN from a prospective longitudinal registry at the Medical University of South Carolina enrolled between 2003 and 2017 were identified if they had renal biopsies with International Society of Nephrology/Renal Pathology Society pathological classification. Clinical laboratory values at the time of diagnosis and outcome variables at approximately 1 year were recorded. Machine learning models were developed and cross-validated to predict suboptimal response.

resultsFive machine learning models predicted suboptimal response status in 10 times cross-validation with receiver operating characteristics area under the curve values >0.78. The most predictive variables were interstitial inflammation, interstitial fibrosis, activity score and chronicity score from renal pathology and urine protein-to-creatinine ratio, white blood cell count and haemoglobin from the clinical laboratories. A web-based tool was created for clinicians to enter these baseline clinical laboratory and histopathology variables to produce a probability score of suboptimal response.

conclusionGiven the heterogeneity of disease presentation in LN, it is important that risk prediction models incorporate several data elements. This report provides for the first time a clinical proof-of-concept tool that uses the five most predictive models and simplifies understanding of them through a web-based application.

Indexed as

Lupus NephritisTool Use BehaviorFemaleHumansKidneyLaboratoriesProspective Studieshealth carelupus erythematosuslupus nephritisoutcome assessmentsystemic

Identifiers

PMID34429335
PMCPMC8386213

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.